Paraoxonase 1: Structure, Function, and Polymorphisms

Anticholinesterase Pesticides: Metabolism, Neurotoxicity, and Epidemiology

Volumn , Issue , 2011, Pages 85-95

  Costa, Lucio G ^a,b   Furlong, Clement E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF PARMA MEDICAL SCHOOL   (Italy)

Author keywords

Paraoxonase 1 (PON1) structure, function and polymorphisms; PON1 polymorphisms with diseases nucleotide polymorphisms with PCR based assays; PON1, as a catalytic scavenger for OP poisoning

Indexed keywords

EID: 84867901469     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470640500.ch7     Document Type: Chapter

References (99)

1. Adkins, S., Gan, K. N., Mody, M., LaDu, B. N. (1993). Molecular basis for the polymorphic forms of human serum paraoxonase/ arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am. J. Hum. Genet. 53, 598-608.
2. Aldridge,W. N. (1953). Serum esterases I. Two types of esterase (A and B) hydrolyzing p-nitrophenyl acetate, proprionate and butyrate and a method for their determination. Biochem. J. 53, 110-117.
3. Ashani, Y., Pistinner, S. (2004). Estimation of the upper limit of human butyrylcholinesterase dose required for protection against organophosphate toxicity: a mathematically based toxicokinetic model. Toxicol. Sci. 77, 358-367.
4. Augustinsson, K. B., Barr, M. (1963). Age variation in plasma arylesterase activity in children. Clin. Chim. Acta 8, 568-573.
5. Benke, G. M., and Murphy, S. D. (1975). The influence of age in the toxicity and metabolism of methylparathion and parathion in male and female rats. Toxicol. Appl. Pharmacol. 31, 254-269.
6. Berkowitz, G. S, Wetmur, J. G., Birman-Deych, E., Obel, J., Lapinski, R. H., Godbold, J. H., Holzman, I. R., Wolff, M. S. (2004). In utero pesticide exposure, maternal paraoxonase activity, and head circumference. Environ. Health Perspect. 112, 388-391.
7. Blatter Garin, M. C., James, R. W., Dussoix, P., Blanche, M., Passa, P., Froguel, P., Ruiz, J. (1997). Paraoxonase polymorphism Met-Leu 54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J. Clin. Invest. 99, 62-66.
8. Brealey, C. B., Walker, C. M., Baldwin, B. C. (1980). A-esterase activities in relation to the differential toxicity of pirimiphosmethyl to birds and mammals. Pestic. Sci. 11, 546-554.
9. Brophy, V. H., Hastings, M. D., Clendenning, J. B., Richter, R. J., Jarvik, J. P., Furlong, C. E. (2001a). Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 11, 77-84.
10. Brophy, V. H., Jampsa, R. L., Clendenning, J. B., McKinstry, L. A., Furlong, C. E. (2001b). Effects of 50 regulatory-region polymorphisms on paraoxonase gene (PON1) expression. Am. J. Hum. Genet. 68, 1428-1436.
11. Brophy, V. H., Jarvik, G. P., Furlong, C. E. (2002). PON1 polymorphisms. In: Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects, Costa L. G., Furlong, C. E., Eds., pp. 53-77. Norwell, MA: Kluwer Academic Publishers.
12. Chambers, J. E., Ma, R., Boone, J. S., Chambers, H.W. (1994). Role of detoxication pathways in acute toxicity of phosphorothioate insecticides in the rat. Life Sci. 54, 1357-1364.
13. Chen, J., Kumar, M., Chan, W., Berkowitz, G. S., Wetmur, J. G. (2003). Increased influence of genetic variation on PON1 activity in neonates. Environ. Health Perspect. 111, 1403-1410.
14. Cherry, N., Mackness, M. I., Durrington, P., Povey, A., Dippnall, M., Smith, T., Mackness, B. (2002). Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip. Lancet 359, 763-764.
15. Cohen, S. D., Murphy, S. D. (1971). Carboxylesterase inhibition as an indicator of malathion potentiation in mice. J. Pharmacol. Exp. Ther. 176, 733-742.
16. Cole, T. B., Jampsa, R. L.,Walter, B. J., Arndt, T. L., Richter, R. J., Shih, D. M., Tward, A., Lusis, A. J., Jack, R. M., Costa, L. G., Furlong, C. E. (2003). Expression of human paraoxonase during development. Pharmacogenetics 13, 1-8.
17. Cole, T. B., Walter, J., Shih, D. M., Tward, A. D., Lusis, A. J., Timchalk, C., Richter, R. J., Costa, L. G., Furlong, C. E. (2005). Toxicity of chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism. Pharmacogenet. Genom. 15, 589-598.
18. Costa, L. G., Furlong, C. E., Eds. (2002). Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects. Norwell, MA: Kluwer Academic Publishers.
19. Costa, L. G., Richter, R. J., Murphy, S. D., Omenn, G. S., Motulsky, A. G., Furlong, C. E. (1987). Species differences in serum paraoxonase correlate with sensitivity to paraoxon toxicity. In: Toxicology of Pesticides: Experimental, Clinical and Regulatory Perspectives, Costa, L. G., Galli, C. L., Murphy, S. D., Eds., pp. 263-266. Heidelberg: Springer- Verlag.
20. Costa, L. G., McDonald, B. E., Murphy, S. D., Omenn, G. S., Richter, R. J., Motulsky, A. G., Furlong, C. E. (1990). Serum paraoxonase and its influence on paraoxon and chlorpyrifosoxon toxicity in rats. Toxicol. Appl. Pharmacol. 103, 66-76.
21. Costa, L. G., Li, W. F., Richter, R. J., Shih, D. M., Lusis, A. J., Furlong, C. E. (2002). PON1 and organophosphate toxicity. In: Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects, Costa, L. G., Furlong, C. E., Eds., pp. 165-183. Norwell, MA: Kluwer Academic Press.
22. Costa, L. G., Cole, T. B., Furlong, C. E. (2003a). Polymorphisms of paraoxonase (PON1) and their significance in clinical toxicology of organophosphates. J. Toxicol. Clin. Toxicol. 41, 37-45.
23. Costa, L. G., Cole, T. B., Jarvik, G. P., Furlong, C. E. (2003b). Functional genomics of the paraoxonase (PON1) polymorphisms: effect on pesticide sensitivity, cardiovascular disease and drug metabolism. Annu. Rev. Med. 54, 371-392.
24. Costa, L. G., Vitalone, A., Cole, T. B., Furlong, C. E. (2004). Modulation of paraoxonase activity. Biochem. Pharmacol. 69, 541-550.
25. Cowan, J., Sinton, C. M., Varley, A.W.,Wians, F. H., Haley, R.W., Munford, R. S. (2001). Gene therapy to prevent organophosphate intoxication. Toxicol. Appl. Pharmacol. 173, 1-6.
26. da Silva, J., Moraes, C. R., Heuser, V. D., Andrade, V. M., Silva, F. R., Kvitko, K., Emmel, V., Rohr, P., Bordin, D. L., Andreazza, A. C., Salvador, M., Henriques, J. A. P., Erdtmann, B. (2008). Evaluation of genetic damage in a Brazilian population occupationally exposed to pesticides and its correlation with polymorphisms in metabolizing genes. Mutagenesis 23, 415-422.
27. Davies, H., Richter, R. J., Kiefer, M., Broomfield, C., Sowalla, J., Furlong, C. E. (1996). The human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nature Genet. 14, 334-336.
28. Deakin, S., Leviev, I., Gomeraschi, M., Calabresi, L., Franceschini, G., James, R. W. (2002). Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high-affinity, saturable, desorption mechanism. J. Biol. Chem. 277, 4301-4308.
29. Draganov, D. I., La Du, B. N. (2004). Pharmacogenetics of paraoxonases: a brief review. Naunyn-Schmiedeberg's Arch. Pharmacol. 369, 78-88.
30. Durrington, P. N., Mackness, B., Mackness, M. I. (2001). Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21, 473-480.
31. Eckerson, H. W., Wyte, C. M., LaDu, B. N. (1983). The human serum paraoxonase/arylesterase polymorphism. Am. J. Hum. Genet. 35, 1126-1138.
32. Ecobichon, D. J., Stephens, D. S. (1973). Perinatal development of human blood esterases. Clin. Pharmacol. Ther. 14, 41-47.
33. Furlong, C. E. (2000). PON1 status and neurologic symptom complexes in Gulf War Veterans. Genome Res. 10, 153-155.
34. Furlong, C. E., Richter, R. J., Chapline, C., Crabb, J. W. (1991). Purification of rabbit and human serum paraoxonase. Biochemistry 30, 10133-10140.
35. Furlong, C. E., Costa, L. G., Hassett, C., Richter, R. J., Sundstrom, J. A., Adler, D. A., et al. (1993). Human and rabbit paraoxonases: purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification. Chem.-Biol. Interact. 87, 35-48.
36. Furlong, C. E., Li, W. F., Richter, R. J., Shih, D. M., Lusis, A. J., Alleva, E., Costa, L. G. (2000). Genetic and temporal determinants of pesticide sensitivity: role of paraoxonase (PON1). Neurotoxicology 21, 91-100.
37. Furlong, C. E., Holland, N., Richter, R. J., Bradman, A., Ho, A., Eskenazi, B. (2006). PON1 status of farmworkers, mothers and children as a predictor of organophosphate sensitivity. Pharmacogenet. Genom. 16, 183-190.
38. Gan, K. N., Smolen, A. L., Eckerson, H. W., LaDu, B. N. (1991). Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab. Dispos. 19, 100-106.
39. Geldmacher-von Mallinckrodt, M., Diepgen, T. L. (1987). The human serum paraoxonase: polymorphism and specificity. Toxicol. Env. Chem. 18, 79-196.
40. Haley, R. W., Billecke, S., LaDu, B. N. (2000). Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans. Toxicol. Appl. Pharmacol. 157, 227-233.
41. Harbison, R. D. (1975). Perinatal development of human blood esterases. Clin. Pharmacol. Ther. 14, 41-47.
42. Harel, M., Aharoni, A., Gaidukov, L., Brumshtein, B., Khersonsky, O., Meged, R., Dvir, H., Revelli, R. B. G., McCarthy, A., Toker, L., Silman, I., Sussman, J. L., Tawfik, D. S. (2004). Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nature Struct. Mol. Biol. 11, 412-419.
43. Hassett, C., Richter, R. J., Humbert, R., Chapline, C., Crabb, J. W., Omiecinski, C. J., Furlong, C. E. (1991). Characterization of DNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry 30, 10141-10149.
44. Hernandez, A. F., Mackness, B., Rodrigo, L., Lopez, O., Pla, A., Gil, F., Durrington, P. N., Pena, G., Passon, T., Serrano, J. L., Mackness, M. I. (2003). Paraoxonase activity and genetic polymorphisms in greenhouse workers with long term pesticide exposure. Hum. Exp. Toxicol. 22, 565-574.
45. Hofmann, J. N., Keifer, M. C., Furlong, C. E., De Roos, A. J., Farin, F. M., Fenske, R. A., van Belle, G., Checkoway, H. (2009). Serum cholinesterase inhibition in relation to paraoxonase-1 (PON1) status among organophosphate-exposed agricultural pesticide handlers. Environ. Health Perspect. 117, 1402-1408.
46. Hotopf, M., Mackness, M. I., Nikolau, V., Collier, D. A., Curtis, C., David, A., Durrington, P., Hull, L., Ismail, K., Peekman, M., Unwin, C., Wessely, S., Mackness, B. (2003). Paraoxonase in Persian Gulf veterans. J. Occup. Environ. Med. 45, 668-675.
47. Humbert, R., Adler, D. A., Disteche, C. M., Omiecinski, C. J., Furlong, C. E. (1993). The molecular basis of the human serum paraoxonase polymorphisms. Nature Genet. 3, 73-76.
48. IOM (Institute of Medicine). (2000). Gulf War and Health. Vol. 1. Depleted Uranium, Pyridostigmine Bromide, Sarin, Vaccines. Washington, DC: National Academy Press.
49. IOM (Institute of Medicine). (2003). Gulf War and Health. Vol. 2. Insecticides and Solvents. Washington, DC: National Academy Press.
50. Jansen, K. L., Cole, T. B., Park, S. S., Furlong, C. E., Costa, L. G. (2009). Paraoxonase 1 (PON1) modulates the toxicity of mixed organophosphorus compounds. Toxicol. Appl. Pharmacol. 236, 142-153.
51. Jarvik, G. P., Rozek, L. S., Brophy, V. H., Hatsukami, T. S., Richter, R. J., Schellenberg, G. D., Furlong, C. E. (2000). Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1192 or PON155 genotype. Arterioscler. Thromb. Vasc. Biol. 20, 2441-2447.
52. Jarvik, G. P., Jampsa, R., Richter, R. J., Carlson, C. S., Rieder, M. G., Nickerson, D. A., Furlong, C. E. (2003). Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status. Pharmacogenetics 13, 291-295.
53. Karanth, S., Pope, C. (2000). Carboxylesterase and A-esterase activities during maturation and aging: relationship to the toxicity of chlorpyrifos and parathion in rats. Toxicol. Sci. 58, 282-289.
54. Lee, B. W., London, L., Poulauskis, J., Myers, J., Christiani, D. C. (2003). Association between human paraoxonase gene polymorphism and chronic symptoms in pesticide-exposed workers. J. Occup. Environ. Med. 45, 118-122.
55. Lenz, D. E., Yeung, D., Smith, J. R., Sweeney, R. E., Lumley, L. A., Cerasoli, D. M. (2007). Stoichiometric and catalytic scavengers as protection against nerve agents toxicity: a mini review. Toxicology 233, 31-39.
56. Leviev, I., James, R. W. (2000). Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler. Thromb. Vasc. Biol. 20, 516-521.
57. Li, W. F., Costa, L. G., Furlong, C. E. (1993). Serum paraoxonase status: a major factor in determining resistance to organophosphates. J. Toxicol. Environ. Health 40, 337-346.
58. Li, W. F., Furlong, C. E., Costa, L. G. (1995). Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol. Lett. 76, 219-226.
59. Li,W. F., Matthews, C., Disteche, C. M., Costa, L. G., Furlong, C. E. (1997). Paraoxonase (PON1) gene in mice: sequencing, chromosomal localization and developmental expression. Pharmacogenetics 7, 137-144.
60. Li, W. F., Costa, L. G., Richter, R. J., Hagen, T., Shih, D. M., Tward, A., Lusis, A. J., Furlong, C. E. (2000). Catalytic efficiency determines the in vivo efficacy of PON1 for detoxifying organophosphates. Pharmacogenetics 10, 767-779.
61. Lotti, M. (2000). Clinical toxicology of anticholinesterases in humans. In: Handbook of Pesticide Toxicology, Krieger, K. R., Ed., pp. 1043-1085. San Diego: Academic Press.
62. Machin, A. F., Anderson, P. H., Quick, M. P., Woddel, D. F., Skibniewska, K. A., Howells, L. C. (1976). The metabolism of diazinon in the liver and blood of species of varying susceptibility to diazinon poisoning. Xenobiotica 6, 104.
63. Mackness, B., Mackness, M. I., Arrol, T., Turkie, W., Durrington, P. N. (1998). Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modifications. FEBS Lett. 423, 57-60.
64. Mackness, B., Durrington, P. N., Mackness, M. I. (2000). Low paraoxonase in Persian Gulf War veterans self-reporting Gulf War Syndrome. Biochem. Biophys. Res. Commun. 276, 729-733.
65. Mackness, B., Davies, G. K., Turkie, W., Lee, E., Roberts, D. M., Hill, E., Roberts, C., Durrington, P. N., Mackness, M. I. (2001). Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler. Thromb. Vasc. Biol. 21, 1451-1457.
66. Mackness, M. S., Mackness, B., Durrington, P. N. (2002). Paraoxonase and coronary heart disease. Artheroscler. Suppl. 3, 49-55.
67. Mackness, B., Durrington, P. N., Povey, A., Thomson, S., Dippnall, M., Mackness, M., Smith, T., Cherry, N. (2003). Paraoxonase and susceptibility to organophosphorus poisoning in farmers dipping sheep. Pharmacogenetics 13, 81-88.
68. Main, A. R. (1956). The role of A-esterase in the acute toxicity of paraoxon, TEEP and parathion. Can. J. Biochem. Physiol. 34, 197-216.
69. Marsillach, J., Mackness, B., Mackness, M., Riu, F., Beltran, R., Joven, J., Camps, J. (2008). Immunohistochemical analysis of paraoxonases-1, 2 and 3 expression in normal mouse tissues. Free Rad. Biol. Med. 45, 146-157.
70. Mazur, A. (1946). An enzyme in animal tissue capable of hydrolyzing the phosphorus-fluorine bond of alkyl fluorophosphates. J. Biol. Chem. 164, 271-289.
71. Mortensen, S. R., Chanda, S. M., Hooper, M. J., Padilla, S. (1996). Maturational differences in chlorpyrifos-oxonase activity may contribute to age-related sensitivity to chlorpyrifos. J. Biochem. Toxicol. 11, 279-287.
72. Moser, V. C., Chanda, S. M., Mortensen, S. R., Padilla, S. (1998). Age- and gender-related differences in sensitivity to chlorpyrifos in the rat reflect developmental profiles of esterase activities. Toxicol. Sci. 46, 211-222.
73. Mueller, R. F., Hornung, S., Furlong, C. E., Anderson, J., Giblett, E. R., Motulsky, A. G. (1983). Plasma paraoxonase polymorphism: a new enzyme assay, population, family biochemical and linkage studies. Am. J. Hum. Genet. 35, 393-408.
74. Murphy, S. D. (1982). Toxicity and hepatic metabolism of organophosphate insecticides in developing rats. Banbury Report 11, 125-136.
75. Ozer, E. A., Pezzulo, A., Shih, D. M., Chun, C., Furlong, C. E., Lusis, A. J., Greenberg, E. P., Zabner, J. (2005). Human and murine paraoxonase 1 are host modulators of Pseudomonas aeruginosa quorum-sensing. FEMS Microbiol. Lett. 253, 29-37.
76. Padilla, S., Buzzard, J., Moser, V. C. (2000). Comparison of the role of esterases in the differential age-related sensibility to chlorpyrifos and metamidophos. Neurotoxicology 21, 49-56.
77. Parker-Katiraee, L., Bousiaki, E., Monk, D., Moore, G. E., Nakabayashi, K., Scherer, S. W. (2008). Dynamic variation in allele-specific gene expression of paraoxonase-1 in murine and human tissues. Hum. Mol. Genet. 17, 3263-3270.
78. Playfer, J. R., Eze, L. C., Bullen, M. F., Evans, D. A. (1976). Genetic polymorphism and interethnic variability of plasma paraoxonase activity. J. Med. Genet. 13, 337-342.
79. Pond, A. L., Chambers, H. W., Chambers, J. E. (1995). Organophosphate detoxication potential of various rat tissues via A-esterase and aliesterase activities. Toxicol. Lett. 70, 245-252.
80. Pope, C. N., Liu, J. (1997). Age-related differences in sensitivity to organophosphorus pesticides. Environ. Toxicol. Pharmacol. 4, 309-314.
81. Pope, C. N., Chakraborti, T. K. (1992). Dose-related inhibition of brain and plasma cholinesterase in neonatal and adult rats following sublethal organophosphate exposure. Toxicology 73, 35-43.
82. Povey, A. C., Jury, F., Dippnall, W. M., Smith, A. E., Thomson, S., Mackness, B., Mackness, M., Durrington, P., Cherry, N. M. (2007). GST, CYP and PON1 polymorphisms in farmers attributing ill health to organophosphate-containing sheep dip. Biomarkers 12, 188-202.
83. Richter, R. J., Furlong, C. E. (1999). Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 9, 745-753.
84. Richter, R. J., Jampsa, R. L., Jarvik, G. P., Costa, L. G., Furlong, C. E. (2004). Determination of paraoxonase 1 status and genotypes at specific polymorphic sites. In: Current Protocols in Toxicology, M. Maines, L. G. Costa, D. J. Reed, E. Hodgson, Eds., pp. 4.12.1-4.12.19. New York: Wiley.
85. Richter, R. J., Jarvik, G. P., Furlong, C. E. (2008). Determination of paraoxonase 1 (PON1) status without the use of toxic organophosphate substrates. Circul. Cardiovasc. Genet. 1, 147-152.
86. Richter, R. J., Jarvik, G. P., Furlong, C. E. (2009). Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicol. Appl. Pharmacol. 235, 1-9.
87. Shih, D. M., Gu, L., Xia, Y. R., Navab, M., Li, W. F., Hama, S., Castellani, L. W., Furlong, C. E., Costa, L. G., Fogelman, A. M., Lusis, A. J. (1998). Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394, 284-287.
88. Sogorb, M. A., Garcia-Arguelles, S., Carrera, V., Vilanova, E. (2008). Serum albumin is as efficient as paraoxonase in the detoxication of paraoxon at toxicologically relevant concentrations. Chem. Res. Toxicol. 21, 1524-1529.
89. Sorenson, R. C., Primo-Parmo, S. L., Kuo, C. L., Adkins, S., Lockridge, O., and La Du, B. N. (1995). Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/ arylesterase. Proc. Natl. Acad. Sci. USA 92, 7187-7191.
90. Sorenson, R. C., Bisgaier, C. L., Aviram, M., Hsu, C., Billecke, S., LaDu, B. N. (1999). Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apoprotein A-1 stabilizes activity. Arterioscler. Thromb. Vasc. Biol. 19, 2214-2225.
91. Sozmen, E. Y., Mackness, B., Sozmen, B., Durrington, P., Girgin, F. K., Aslan, L., Mackness, M. (2002). Effect of organophosphate intoxication on human serum paraoxonase. Hum. Exp. Toxicol. 21, 247-252.
92. Stevens, R. C., Suzuki, S. M., Cole, T. B., Park, S. S., Richter, R. J., Furlong, C. E. (2008). Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning. Proc. Natl. Acad. Sci. USA 105, 12780-12784.
93. Suehiro, T., Nakamura, T., Inoue, M., Shiinoki, T., Ikeda, Y., Kumoin, Y., Shindo, M., Tanaka, H., Hashimoto, K. (2000). A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis 150, 295-298.
94. Suzuki, T., Morito, H., Ono, K., Mackawa, K., Nagai, R., Yazaki, Y. (1995). Sarin poisoning in Tokyo subway. Lancet 345, 980-981.
95. Sweeney, R. E., Maxwell, D. M. (2003). A theoretical expression for the protection associated with stoichiometric and catalytic scavengers in a single compartment model of organophosphorus poisoning. Math. Biosci. 181, 133-143.
96. Timchalk, C., Kousba, A., Poet, T. S. (2002). Monte Carlo analysis of the human chlorpyrifos oxonase (PON1) polymorphism using a physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model. Toxicol. Lett. 135, 51-59.
97. Yamada, Y., Takatori, T., Nagao, M., Iwase, H., Kurada, N., Yanagida, J., Shinozuka, T. (2001). Expression of paraoxonase isoform did not confer protection from acute sarin poisoning in the Tokyo subway terrorist attack. Int. J. Leg. Med. 115, 82-84.
98. Yamasaki, Y., Sakamoto, K., Watade, H., Kajimoto, Y., Hori, M. (1997). The Arg192 isoform of paraoxonase with low sarinhydrolyzing activity is dominant in the Japanese. Hum. Genet. 101, 67-68.
99. Zech, R., Zurcher, K. (1974). Organophosphate splitting serum enzymes in different mammals. Comp. Biochem. Physiol. B 48, 427-433.